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Abstract
Background: Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and 
pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of 
olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%), patients experienced symptoms 
suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" 
(PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur.
Methods: Healthcare providers involved in the PDSS cases were queried for clinical information around the events. 
Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine 
concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials 
from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user 
error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro 
experiments were conducted to assess solubility of olanzapine pamoate in various media.
Results: Injection administrators reported no unusual occurrences during the injection. No anomalies were found with 
the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events 
were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases 
reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 
24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in 
plasma than in other media such as those approximating the environment in muscle tissue.
Conclusions: Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as 
possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to 
exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended 
partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection 
technique) with subsequent seepage of the medication into the vasculature, which would produce higher than 
intended olanzapine concentrations and symptoms consistent with PDSS.
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Background
Post-injection delirium/sedation syndrome (PDSS), also
known as post injection syndrome, is a serious adverse
event observed in a small percentage of patients treated
with olanzapine long-acting injection (LAI), following
approximately 0.07% of injections [1]. Characterized by
symptoms related to excessive sedation and/or delirium
that occur in temporal proximity to the injection, the syn-
drome appears consistent with some of the symptoms of
oral olanzapine overdose [2]. When the first case was fol-
lowed by 2 subsequent independent cases close in time,
intensive investigations were initiated to understand
these occurrences. As additional cases occurred, hypoth-
eses emerged and were evaluated regarding the possible
mechanism or mechanisms behind these events.
Because the first such PDSS case revealed unexpectedly
high olanzapine concentrations at the time of the PDSS
event, it was hypothesized from that first case and those
subsequently observed that these events were likely the
result of too much olanzapine entering the systemic cir-
culation more rapidly than intended. Olanzapine LAI is
composed of an aqueous suspension of a poorly soluble
salt (olanzapine pamoate monohydrate). Typical perfor-
mance is such that almost immediately upon injection of
the suspension, a slow dissolution of the olanzapine
pamoate monohydrate salt begins at the intramuscular
site of injection and systemic olanzapine concentrations
are measurable within minutes to hours. Dissolution of
the dose then continues slowly over a period of weeks
providing sustained, therapeutic systemic concentrations
of olanzapine. These concentrations typically reach a
peak within the first week after the injection and then
gradually decline over the next few weeks, allowing the
medication to be injected every 2 to 4 weeks [3]. Similar
solubility-limited salt-based depot formulations are
known to be advantageous because they provide a slow
extended dissolution over a prolonged time while also
permitting the dissolution process to begin quickly,
allowing for an immediate onset of action from absorp-
tion of the disassociated components (in this case, olan-
zapine and pamoic acid) into the bloodstream [4,5]. For
the olanzapine LAI formulation, it is important to note
that after every injection except those resulting in a PDSS
event, the olanzapine concentration profile does not
show any rapid initial release such as a "burst" or a "dose
dumping" effect [6] in which a larger amount of the drug
is released initially upon injection. Instead, olanzapine
concentrations increase slowly after the olanzapine LAI
injection, and the slow depot release maintains the olan-
zapine concentration within a range of approximately 5 to
73 ng/mL (10th percentile for 150 mg/2 weeks to 90th
percentile for 300 mg/2 weeks at steady state) [5], which
is within the range resulting from within-label oral olan-
zapine doses [7-9].
Given this pharmacokinetic profile, the occurrence of a
single discrete episode of unexpectedly high olanzapine
concentrations in some patients soon after intramuscular
injection did not appear to have a clear explanation.
Hypothesized root causes included product quality
issues, errors in reconstitution, inappropriate dosing or
administration of the medication, or unanticipated
behavior of the formulation under certain physiological
conditions, such as accidental intravascular injection. We
investigated these potential causes through the following:
1) review of product quality controls, 2) analysis of
unused suspension remaining in the product vials of the
PDSS cases, 3) review of information from the injection
administrators and healthcare personnel involved in the
cases for any notable occurrences during the injection
process or apparent proximate causes of the event, 4)
analysis of plasma samples collected during the PDSS
events, and 5) analysis of both the solubility and intrinsic
in-vitro dissolution rate of olanzapine pamoate in various
media representative of physiological fluids (specifically,
blood versus the muscle tissue environment). The key
findings from these investigations are described below.
Method
Description of PDSS events
A description of the 8 clinical trials and the patient popu-
lations on which these analyses are based as well as a
description of the first 30 cases of PDSS observed during
olanzapine LAI trials are presented by Detke et al. in a
companion article [2]. All study protocols were approved
by institutional review boards at each site. After receiving
a complete description of the study, all patients and/or
their authorized legal representatives provided written
informed consent before participation.
Vial and product quality investigation
Manufacturing records including clinical trial lot
approval and stability reports were reviewed for those
lots of olanzapine LAI involved in PDSS events and for
those not involved in PDSS events. The physicochemical
properties examined included the crystal form and the
particle size (or surface area available for dissolution),
which are factors that can affect the rate of olanzapine
release if outside the limits specified by the manufactur-
ing process. Manufacturing records were examined to
confirm that drug lots met established control standards
during manufacturing and to determine whether there
were any trends toward smaller particle size, whether
particle size changed upon storage, and whether there
was homogeneity of particle size distribution from vial to
vial.
In addition, when possible, used product vials from the
PDSS events were collected for analysis. If an injection
resulted in a PDSS event, the healthcare provider wasMcDonnell et al. BMC Psychiatry 2010, 10:45
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requested to return the leftover vial of reconstituted olan-
zapine pamoate suspension as well as the leftover diluent
vial that had been used to suspend the olanzapine pamo-
ate powder. Vials were analyzed to confirm drug product
identity and concentration as well as other product char-
acteristics such as pH, crystal morphology, and particle
size.
Information from clinical sites
Clinical trial investigators provided detailed reports on
the PDSS events within 24 hours of the time they
occurred. Follow-up was conducted with site personnel
either by telephone or during a site visit to gather addi-
tional details around the events and to clarify statements
in the original event reports. Interactions with site per-
sonnel who had been involved in these cases also
occurred through various clinical trial meetings and
training sessions, allowing for the opportunity to discuss
clinical impressions and explore possible proximate
causes that may have been apparent in the clinic prior to,
during, or after the injection.
Pharmacokinetic investigations
Plasma samples were collected from blood prospectively
in some but not all of the olanzapine LAI clinical trials.
After the discovery of the PDSS phenomenon, investiga-
tors in all ongoing trials were requested to collect plasma
samples within the first 2 hours of onset of the PDSS
event and then at approximately 4, 8, 16, 24, and 72 hours
after onset or until symptoms resolved. If patients were
sent to the hospital for further monitoring, it was
requested that such samples be collected by the hospital
when possible. Plasma samples were analyzed using vali-
dated methodology that included high performance liq-
uid chromatography (HPLC) with electrochemical
detection based on Catlow et al. [10] to determine the
concentration of olanzapine in each sample. The concen-
tration measurements were conducted by BASi in West
Lafayette, IN, USA. Concentrations over time were
g r a p h i c a l l y  a s s e s s e d  a n d  c o m p a r e d  t o  t h e  d a t a b a s e  o f
olanzapine plasma concentrations from clinical trials that
spanned the corresponding range of doses for once daily
oral olanzapine and every-2-to-4-week doses of olanzap-
ine LAI [3,8,2].
Solubility and intrinsic dissolution rate investigations
Two types of investigations were conducted in-vitro to
compare the rate of dissolution of olanzapine pamoate
monohydrate in various media. The first set of experi-
ments assessed equilibrium solubility by placing an
excess of olanzapine pamoate monohydrate in contact
with a liquid medium to determine the maximum
amount of the salt that could be dissolved per mL of fluid.
Materials for the equilibrium solubility experiments
included olanzapine pamoate monohydrate; human
plasma (pH = 7.67) from Biological Specialty Corp, Col-
mar, PA; USP pH 7.68 phosphate buffer; USP pH 6.80
phosphate buffer; and plasma ultrafiltrate (plasma passed
through a 10,000 molecular weight filter in order to
remove proteins and lipids). Human plasma was the pri-
mary medium of interest and was used to understand
whether the solubility of olanzapine pamoate changes if it
comes into contact with substantial quantities of blood.
The pH 7.68 buffer was selected because it had the same
pH as the plasma lots used, and the pH 6.80 buffer was
used as a reference medium because this buffer had been
used in prior in-vitro dissolution studies done as part of
the preclinical development for olanzapine pamoate
[unpublished data]. These aqueous buffers were used as a
proxy for the extracellular fluid of muscle tissue. The pur-
pose of including the plasma ultrafiltrate was to assess the
importance of proteins and lipids present in the plasma
upon the solubility and dissolution of olanzapine pamo-
ate and to be a further surrogate or proxy for the extracel-
lular fluid in muscle tissue.
For the plasma and plasma ultrafiltrate equilibrium sol-
ubility in-vitro experiments, 8 mg olanzapine pamoate
monohydrate was placed in a vial and then the appropri-
ate medium was added; for the phosphate buffer analyses,
2 mg of olanzapine pamoate monohydrate was used. The
samples were placed into a heated 37°C precision water
bath and then shaken continuously. Liquid sample frac-
tions were obtained after approximately 24 and 48 hours.
The samples were centrifuged at 5000 rpm for 10 minutes
prior to their preparation for analysis. Analysis of samples
was conducted in triplicate for each medium. Olanzapine
concentrations were determined by liquid chromatogra-
phy-mass spectrometry.
The second type of experiment assessed intrinsic disso-
lution rate (IDR), which measures the rate at which olan-
zapine pamoate dissolves by exposing a constant surface
area of a compressed pellet of the salt to sink condition
for the various media. Materials for the IDR experiment
were olanzapine pamoate monohydrate, human plasma
(pH = 7.46) from Biological Specialty Corp, Colmar, PA,
and USP pH 7.46 phosphate buffer. Air was removed
from the phosphate buffer by purging with helium for 5
minutes and from the plasma by sonification for 5 min-
utes. For each assessment, 100 mg of olanzapine pamoate
monohydrate was compressed using a Carver Press at a
pressure of 3000 pounds for 1 minute to produce a pellet
of the salt with a surface area of 0.5 cm2. The pellet was
placed into 500 mL of the media in a dissolution bath
using a Wood's apparatus set to a rotation of 100 rpm at a
temperature of 37°C. Samplings of 1 mL per time point
were collected at 1, 5, 10, 15, 20, 30, 45, 60, 120, and 180
minutes, and the olanzapine pamoate concentration in
each sample was analyzed using liquid chromatography-
mass spectrometry. The IDR experiments for each of theMcDonnell et al. BMC Psychiatry 2010, 10:45
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media (plasma and aqueous buffer) were performed in
triplicate. The integrity of the pellet was checked visually
to establish whether a constant surface area was main-
tained during the experiment.
Results
Vial and product quality analyses
All drug lots met established standards during their man-
ufacturing. Approval and stability data for the drug lots
i n volved i n PDS S cases  w e r e  c om par a ble  t o da ta  fr om
other clinical trial lots in which PDSS was not observed.
Clinical trial lot data used to approve the lots for clinical
use indicated that there have been no lots with significant
amounts of small particles. The particle size distributions
for the lots involved in the PDSS cases were consistent
with the particle size distributions tested in a clinical
pharmacology study (Study F1D-EW-LOBS,
NCT00094640) and within the limits specified by the
manufacturing process, within which there is no impact
on the pharmacokinetic profile of olanzapine LAI. Fur-
thermore, the particle size distribution of these drug lots
did not change upon storage, and homogeneity of the
drug product particle size distribution from vial to vial
was demonstrated.
Eleven used olanzapine pamoate vials and 10 used
diluent vials were collected from the PDSS cases. The
residual suspension in all 11 olanzapine pamoate vials
exhibited the expected physicochemical properties (i.e.,
potency, related substances, pH, particle size, and crystal
morphology). The 10 returned diluent vials were all con-
firmed to be the appropriate diluent. These analyses indi-
cated no evident errors in drug reconstitution by the site
and no product quality issues.
Follow-up information from clinical investigators
Healthcare personnel involved in the PDSS events did not
report any difficulties or peculiarity with the administra-
tion of the injection itself. They did not observe signifi-
cant blood return at the site of the injection either upon
aspiration of the syringe prior to injection or following
the injection, other than what would be considered typi-
cal, nor did they note any hematoma or other anomalies
at the site of injection either before or after the injection.
Questioning of the site personnel revealed that the injec-
tion administrators were typically nurses with significant
clinical experience in performing intramuscular gluteal
injections, although there was a range of experience
noted and also in some cases the physician performed the
injection. Investigators did not report variation from the
usage of the 1.5-inch (or 35 mm) 19-gauge needle sup-
plied with the medication. Although a 2-inch (or 50 mm)
needle was also available for use with obese patients, nee-
dle length did not appear to be a factor in the events.
Analysis of the anecdotal reports from the sites regarding
specific cases did not identify any common factor among
the cases that could be viewed as a potentially proximate
cause of the event.
Pharmacokinetic analyses
Figure 1 presents olanzapine plasma concentrations for
the first case of PDSS [2], which occurred during the con-
duct of a pharmacokinetic study [11], allowing for analy-
sis of olanzapine concentrations over the course of 6
monthly injections. The patient (a male smoker) received
his first injection of olanzapine LAI at a dose of 300 mg/4
weeks. The pharmacokinetic profile for this first injection
was generally consistent with the typical profile at this
dose, with the patient's olanzapine concentrations over
the dosing interval averaging approximately 17 ng/mL.
Forty-five minutes after the second injection, the patient
experienced severe sedation as well as other symptoms of
PDSS, including disorientation, dizziness, weakness, and
tension in the legs. The patient slept and then had a blood
sample drawn at approximately 6 hours after injection
that revealed an olanzapine concentration of 172.75 ng/
mL, which was above the expected range for this patient
or this dose. At that 6-hour time point, the patient felt
better but remained sleepy. Olanzapine concentrations
returned to a normal range over the next 24 to 48 hours,
and all symptoms of PDSS had resolved by 24 hours after
injection. The patient continued in the trial, although at a
Figure 1 Olanzapine plasma concentrations across multiple in-
jections in a patient with a PDSS event. The figure illustrates the 
olanzapine plasma concentration profiles after 6 different olanzapine 
LAI injections in one patient who experienced a PDSS event at the sec-
ond injection. Arrows below the x-axis indicate injections. Higher than 
expected olanzapine plasma concentrations were measured at 6 and 
24 hours after the second injection, with concentrations returning to 
the expected therapeutic range after 48 hours. Olanzapine concentra-
tions at subsequent injections remained in the expected therapeutic 
range. The dashed line indicates 100 ng/mL; all of the assessed PDSS 
cases had maximum olanzapine concentrations higher than this value.
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lower dose (200 mg/4 weeks), receiving 4 more injections
as per protocol, with no further PDSS events and with
olanzapine concentrations that were generally consistent
with other patients at this dose level.
Plasma samples were collected for a total of 12 of the 30
PDSS injection events. Figure 2 illustrates the olanzapine
plasma concentrations measured over time during these
events. In all 12 cases, observed olanzapine concentra-
tions exceeded the expected range of concentrations for
these doses. Because there were only a limited number of
samples obtained during and after an event, it is not
known that these were the highest or peak olanzapine
concentrations during the event. However, the concentra-
tion pattern from these data demonstrated a substantial
increase in olanzapine concentrations to supratherapeu-
tic levels in the hours after the injection, followed by a
gradual return to typical levels over the next 24 to 72
hours, concordant with the resolution of the event's clini-
cal symptoms. Figure 3 presents the maximum observed
olanzapine plasma concentrations during the events by
dose. There was not a consistent relationship between
maximum olanzapine concentration measured during
the event and dose injected, suggesting that PDSS events
can occur after giving any olanzapine LAI dose and that
dose size is not a principal factor.
Finally, while the olanzapine plasma concentrations in
the hours immediately following the onset of a PDSS
event were substantially elevated, appropriate therapeutic
concentrations were maintained for the remainder of that
injection interval. Therefore, despite the apparently early
and excessively fast release of a portion of the olanzapine
LAI dose, some portion of the dose appeared to continue
to provide a slow and sustained release of olanzapine over
a period of weeks, consistent with the expected perfor-
mance characteristics of a depot.
Solubility and intrinsic dissolution rate investigations
Table 1 reports the equilibrium solubility results for olan-
zapine pamoate in various media. Results from the 24-
and 48-hour tests were similar. However, there was some-
what less variability between replications at the 48-hour
time period suggesting that the 48-hour results approach
equilibrium. At the 48-hour sampling time, mean solubil-
ity of olanzapine pamoate in plasma (0.986 mg/mL) was
established to be substantially higher than in other media
studied, including plasma ultrafiltrate (0.176 mg/mL);
phosphate buffer pH 7.68 (0.060 mg/mL); and phosphate
buffer pH 6.80 (0.016 mg/mL). The pH 7.68 buffer results
were in excellent agreement with and replicated historical
solubility results [unpublished data], thus suggesting that
any differences in procedures used in the current solubil-
ity studies did not introduce a bias.
The intrinsic dissolution rate experiments indicated
that the rate of dissolution of olanzapine pamoate in
plasma (0.73 mg/hr·cm2) was approximately 6 times
higher than in the phosphate buffer (pH 7.46 = 0.12 mg/
hr·cm2). The faster rate of in-vitro dissolution in plasma
i s  c o n s i s t e n t  w i t h  t h e  f i n d i n g  o f  h i g h e r  s o l u b i l i t y  i n
plasma and consistent with the established Noyes-Whit-
ney theory predicting that for a constant surface area, the
intrinsic rate of dissolution increases with an increase in
the equilibrium solubility of the solute in the medium
[12,13].
Figure 2 Olanzapine plasma concentrations observed over time 
in PDSS events. The figure shows olanzapine plasma concentrations 
from the time of the injection associated with the PDSS event up to 72 
hours after that injection. Olanzapine plasma concentration values 
plotted at time 0 hour (pre-injection) that anchor the concentration 
curves are either based on the patient's data for measurements made 
before other injections or are presumed to be approximately 20 ng/mL 
based on the general population's typical pre-injection concentration. 
Only the data after injection (samples collected beyond 0 hour) are ac-
tual measurements for samples collected for these events. Case num-
bers correspond to the cases presented in Detke et al [2].
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Discussion
Olanzapine pamoate is an insoluble salt-based depot for-
mulation that is designed to release olanzapine slowly at
the site of the intramuscular gluteal injection over the
course of several weeks. The occurrence of a small num-
ber of events marked by excessive sedation and/or delir-
ium occurring within 1 to 3 hours after the injection,
typically within the first hour [2], resulted in our investi-
gating the possible reason(s) for these occurrences. Those
investigations did not uncover any evidence suggesting
manufacturing irregularities or human error as possible
causes of these events. Instead, the converging evidence
indicates that this post-injection syndrome, with its clini-
cal presentation consistent with olanzapine overdose, is
related to a more rapid than intended dissolution of a
portion of the olanzapine LAI dose in the hours soon
after the injection, resulting in higher than intended olan-
zapine plasma concentrations during the post-injection
period. This inadvertent early release of olanzapine can
occur if olanzapine LAI comes into contact with a sub-
stantial volume of blood. Intended for intramuscular
injection only, olanzapine LAI could potentially come
into contact with blood through various mechanisms but
most likely as a result of accidental intravascular injection
Table 1: Solubility of olanzapine pamoate monohydrate in various media determined at 24 and 48 hours (37°C)
Medium (time in hours) Solubility (mg/mL) Mean Solubility (mg/mL)
Plasma (24 hr) 0.986 0.918
Repeat #1 0.935
Repeat #2 0.832
Plasma (48 hr) 1.090 0.986
Repeat #1 0.890
Repeat #2 0.978
Plasma ultrafiltratea (24 hr) 0.150 0.187
Repeat #1 0.236
Repeat #2 0.176
Plasma ultrafiltrate (48 hr) 0.160 0.176
Repeat #1 0.161
Repeat #2 0.207
pH 7.68 buffer (24 hr) 0.058 0.052
Repeat #1 0.053
Repeat #2 0.044
pH 7.68 buffer (48 hr) 0.072 0.060
Repeat #1 0.063
Repeat #2 0.046
pH 6.80 buffer (24 hr) 0.024 0.013
Repeat #1 0.007
Repeat #2 0.008
pH 6.80 buffer (48 hr) 0.016 0.016
Repeat #1 0.012
Repeat #2 0.021
aPlasma ultrafiltrate (i.e., plasma filtered for proteins and lipid particles) was used to assess the importance of the presence of proteins and 
lipids upon solubility and dissolution of olanzapine pamoate monohydrateMcDonnell et al. BMC Psychiatry 2010, 10:45
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or blood vessel injury during the intramuscular injection
process.
Pharmacokinetic analyses
Excessive olanzapine concentrations
Although the olanzapine plasma concentration data
obtained during PDSS injection events were sparse, the
pattern emerging from these data indicated the presence
of excessive concentrations of olanzapine in the hours
immediately after the injection. These findings parallel
the clinical findings [2], which indicated symptoms con-
sistent with olanzapine overdose. Moreover, the timing of
the symptoms and their resolution appeared to corre-
spond to the concentration-time profile, with symptoms
resolving and olanzapine concentrations returning to the
expected range within 24 to 72 hours.
No clear correlation with dose
Maximum olanzapine concentrations during the event
did not appear to correlate with dose. Although olanzap-
ine pharmacokinetic characteristics are associated with
wide interpatient variability in olanzapine plasma con-
centrations, an evaluation of the available pharmacoki-
netic databases for various formulations of olanzapine
indicate that plasma concentrations for olanzapine gener-
ally demonstrate dose-proportional increases [14]. How-
ever, results for the PDSS cases found no consistent
pattern across cases. For example, the lowest observed
PDSS peak olanzapine concentration occurred after
administration of the largest olanzapine LAI dose (405
mg), suggesting that only a portion of the dose was
released into systemic circulation prematurely. Also,
PDSS events have occurred after doses of 195 to 405 mg
olanzapine LAI doses, representing nearly the full spec-
trum of therapeutic dose strengths (150 to 405 mg). Thus,
the variability in observed olanzapine concentrations for
the PDSS cases most likely relates more strongly to the
portion of the dose that prematurely enters the systemic
circulation rather than to the total dose injected.
Solubility
The solubility of olanzapine pamoate monohydrate in
plasma was shown to be substantially higher than in
aqueous media approximating the extracellular fluid in
muscle tissue. Greater solubility of olanzapine pamoate in
blood than in the fluid bathing the muscle tissue affords
the basis for a theory as to the mechanism leading to the
observed excessive systemic olanzapine concentrations
associated with PDSS events. Because of this greater sol-
ubility, a faster rate of dissolution of the pamoate salt
would occur as a result of contact between the injectabl
esuspension of drug product, olanzapine LAI, and a sub-
stantial quantity of blood. That is, if olanzapine pamoate
monohydrate were exposed to a sufficiently large volume
of blood, an amount of olanzapine that approaches the
equilibrium solubility of the salt could dissolve. Under
static conditions, a hematoma consisting of 20 mL blood
w o u l d  a p p e a r  t o  b e  r e q u i r e d  f o r  t h e  d i s s o l u t i o n  o f
approximately 20 mg olanzapine (based upon the 0.986
mg/mL estimate for equilibrium solubility of olanzapine
pamoate in plasma). This amount of olanzapine is a
widely used oral dose, and would not be expected to lead
to profound sedation, even if that amount were to gain
rapid access into the bloodstream. Moreover, a hema-
toma much larger than this would likely be detectable by
the patient or clinician. Therefore, a more plausible the-
ory is that in order to dissolve the amount of olanzapine
needed to achieve the observed concentrations and to
produce the observed clinical effects, the olanzapine LAI
would need to be exposed to a substantial amount of
blood, the volume of which would likely require a contin-
uous flow. Blood flow would also aid dissolution of the
olanzapine pamoate through the motion or agitation in
the bloodstream. Thus, a substantial amount of olanzap-
ine could be rapidly dissolved even if only a portion of the
olanzapine LAI dose were accidentally injected into a
b l o o d  v e s s e l  o r  i f  t h e  n e e d l e  a c c i d e n t a l l y  n i c k e d  o r
pierced a proximal vessel during the injection process,
providing a track to access the bloodstream (Figure 4).
Probable mechanism
Accidental intravascular injection of drugs intended for
intramuscular injection is a recognized risk of this route
of administration [15-20], and there is evidence that
intramuscularly injected medications can enter the vas-
culature [21]. Although not all accidental intravascular
injections would necessarily produce noticeable symp-
toms, one intramuscularly injected medication with a
clinically distinguishable and well characterized post
injection syndrome is penicillin procaine G [16,22]. This
procaine-penicillin salt can produce a reaction known as
Hoigne's syndrome following accidental intravascular
injection [16] as the salt rapidly dissolves in blood, allow-
ing free base procaine to penetrate the brain in excessive
Figure 4 Illustration of proposed mechanism for olanzapine LAI 
distribution (in yellow) after vessel damage by nicking. The figure 
illustrates the proposed mechanism for distribution of the olanzapine 
LAI suspension during a PDSS event. The first panel depicts the tip of 
the syringe needle piercing the wall of the blood vessel situated within 
the muscle bed. In the second panel, the medication (in yellow) has 
been injected into the muscle tissue and is leaking into the blood ves-
sel through the punctured vessel wall.
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amounts and causing mental confusion. As occurs with
the penicillin-procaine salt, direct entry of the olanzapine
pamoate salt into the bloodstream would substantially
enhance its rate of dissolution, especially under the phys-
iological conditions in which a continuous flow of blood
occurs. Continuous blood flow could promote the release
of a substantial amount of olanzapine over a period of
minutes to hours.
It should be noted that a direct intravascular injection
of the full dose of olanzapine LAI would be difficult to
achieve. The features of the delivery device (i.e., a 19-
gauge needle) and the properties of the olanzapine LAI
injection (i.e., a viscous suspension of solid material hav-
ing a total injection volume between 1.5 to 3.0 mL),
impose physical limitations that make accidental intra-
vascular injection of the full dose highly improbable. The
needle diameter and long bevel make accidental cannula-
tion of a blood vessel highly unlikely, and such placement
of the needle would results in blood aspiration before giv-
ing the injection. Nonetheless, even if the needle were
accidentally positioned completely inside a blood vessel,
the injection of up to 3.0 mL of the olanzapine LAI sus-
pension would likely obstruct blood flow through that
vessel and only result in a portion of the dose going into
the circulation. Considering the needle size, the injection
volume, the physical properties of the suspension of olan-
zapine pamoate, and prescribed intramuscular injection
technique, it is likely that only a portion of the olanzapine
LAI dose can accidentally be injected into the blood-
stream. These physical limitations to a full intravascular
injection are consistent with the pharmacokinetic find-
ings, which suggest that only a portion of the dose enters
the vasculature prematurely.
Ultimately, the potential mechanisms by which the sus-
pension comes into contact with blood could be various.
For instance, direct injection into a blood vessel may be
one method, but nicking a blood vessel during the injec-
tion process (Figure 4), pooling of a large quantity of
blood at the site of the drug deposit in the muscle, or
injection into a rich capillary bed could also be possibili-
ties. Although proper intramuscular injection technique
is important to minimize the risk of a PDSS injection
event, the PDSS events still occurred even when proper
technique was being used. Proper injection technique
would only avoid placement of the tip of the needle
directly inside a vessel, but other forms of blood vessel
involvement could still occur. For example, if the needle,
when inserted, passed completely through a blood vessel,
aspiration of the syringe would not necessarily yield
blood because the tip of the needle would no longer be
located in the blood vessel. The injection administrator
would then inject the bolus of medication into the muscle
beyond or in near proximity to the punctured blood ves-
sel. However, when the needle was withdrawn, the medi-
cation could then track back and enter the blood vessel at
the site of the puncture. Therefore, a negative finding
upon aspiration is not necessarily indicative that the
medication has not or will not come into contact with
blood. This explanation would be consistent with the
reports by the injection administrators that they had used
correct injection technique at the time of the events. It
would also be consistent with the finding that the PDSS
rate of occurrence remained consistent over the course of
the clinical trials despite additional injection technique
training for the clinical sites. This consistency of PDSS
rate over time, despite further training and increased vig-
ilance with regard to injection technique, suggests that
this rate (0.07% of injections) may reflect the naturally
occurring background rate of accidental blood vessel
contact (puncture or nicking) during intramuscular injec-
tions. This conjecture appears to be further supported by
the finding of a very similar rate (0.08% of injections) for
the penicillin procaine G post-injection reaction known
as  H o i gn e ' s  syn d r o m e  [ 1 6 ] ,  w h i c h  i s  a ls o  p r e s u m ed  t o
occur through the mechanism of inadvertent intravascu-
lar injection, irrespective of good injection technique.
Proposed mechanism and timing of onset of PDSS
One seemingly contradictory finding would appear to be
the timing of onset of the clinical symptoms of PDSS.
Symptoms of accidental intravascular injection of medi-
cations are often assumed to be nearly instantaneous fol-
lowing injection (as is the case with dental anesthetics).
However, for olanzapine LAI, data instead suggest that
the increase in olanzapine systemic exposure during a
PDSS injection event progressed over a period of hours.
This course also corresponds to the observed clinical
course [2], in that symptoms in some cases took an hour
or more to appear, and in almost all cases, symptoms of
the syndrome gradually evolved over the course of min-
ut es  t o  hour s r a t he r t ha n sec on ds.  T his pr ogr es si on is
likely attributable to the fact that the olanzapine pamoate
monohydrate salt must first dissolve and then dissociate
into its components, olanzapine and pamoic acid. Thus,
even when there is substantial contact between the sus-
pension and blood, complete dissolution of olanzapine
LAI will not occur immediately. Consequently, the rate of
change in systemic olanzapine concentration is much less
rapid, changing over a period of hours during a PDSS
event rather than the almost instantaneous increase that
would occur if a solution of olanzapine base (as opposed
to olanzapine pamoate salt) were to be injected intrave-
nously or even intramuscularly. Although the increase in
olanzapine concentrations during a PDSS event is still
much faster than intended for this slow-release depot for-
mulation, the fact that this premature release occurs
more gradually than a direct injection of an olanzapineMcDonnell et al. BMC Psychiatry 2010, 10:45
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solution may also account for the lack of cardiorespira-
tory depression seen in any of the PDSS cases to date [2].
There has also been a wide variability in the timing of
onset of PDSS symptoms, with onset times ranging from
immediately after the injection to as late as 3 or more
hours after injection. The length of the delay between
time of injection and time of first PDSS symptoms is
likely dependent on a number of factors, including the
size of the affected blood vessel, the degree of vascular
injury, the volume and rate of blood flow at the site of
injury, the amount of olanzapine pamoate coming into
direct contact with a substantial quantity of blood, and
perhaps patient-specific factors such as clotting speed. It
is therefore the variable rate of dissolution of olanzapine
LAI under the variable physical conditions or situations
leading to a PDSS injection event that likely influences
not only the time of onset but also the intensity of the
adverse events associated with a PDSS injection event.
Given the potential for variability in the confluence of the
many factors impacting the time course of a PDSS injec-
tion event, it is possible that an event could begin soon
after injection (e.g., if a major blood vessel received a
larger injury) or could be delayed for hours (e.g., if a
smaller blood vessel received a smaller injury, if a small
injury during the injection process were later exacerbated
by additional physical factors, or if the distance along the
injection track between the injury and the deposited
medication were longer).
As for whether other mechanisms could explain PDSS
events, any explanation would need to account for the
elevated systemic olanzapine concentrations during the
event. Therefore, the mechanism must entail the dissolu-
tion and absorption of a greater portion of the dose ini-
tially than is expected for this depot formulation. It is
possible that this early and time-limited increase in solu-
bility could be accounted for by other means or that
excessive contact between olanzapine pamoate and blood
could occur through means other than accidental blood
vessel injury during the injection process. Although there
was no indication that massage of the injection site, mus-
cle injury, or high-pressure injection was involved with
any of the events, we cannot definitively rule these out as
contributors to the events. With regard to massage at the
injection site, current administration instructions state
that massage of the injection site should not be per-
formed. Also, typical injection forces for olanzapine LAI
are low. In an in-vitro compression test, typical injection
forces were measured to be approximately 2 pounds of
force, which in our testing was less than that required to
inject other depot medications. In the event of a needle
clog, it is possible that the injection force could be higher;
however, there has been no evidence to suggest that high
injection pressure was a contributing factor in any of the
events seen to date. Further research would be needed to
develop and/or confirm other possible explanations.
Conclusions
All existing data point to accidental contact between
olanzapine LAI and blood as the proximate cause of
PDSS. Patients experiencing PDSS events had demon-
strably higher than expected systemic concentrations of
olanzapine only at the time of the PDSS event. The phar-
macokinetic profile during these events indicated a more
rapid release of olanzapine than normally intended dur-
ing the hours immediately after the injection but with
concentrations returning to expected levels for the
remainder of the injection interval. Product quality issues
and administrator error were ruled out as possible causes.
Because olanzapine pamoate is substantially more soluble
in blood than in the fluid bathing the muscle tissue and
consequently dissolves more rapidly in blood, the most
likely explanation for PDSS is that a portion of the intra-
muscularly injected olanzapine pamoate dose acciden-
tally enters the bloodstream as a result of injury to a
blood vessel during the injection process, effectively
resulting in intravascular injection of a limited portion of
the olanzapine LAI dose.
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